Abstract
We report a case of a 31-year-old man with metastatic fibrolamellar hepatocellular carcinoma (FLHCC) treated with gemcitabine and oxaliplatin complicated by hyperammonemic encephalopathy biochemically consistent with acquired ornithine transcarbamylase deficiency. Awareness of FLHCC-associated hyperammonemic encephalopathy and a pathophysiology-based management approach can optimize patient outcome and prevent serious complications. A discussion of the management, literature review, and proposed treatment algorithm of this rare metabolic complication are presented.
Cite
CITATION STYLE
Chapuy, C. I., Sahai, I., Sharma, R., Zhu, A. X., & Kozyreva, O. N. (2016). Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. The Oncologist, 21(4), 514–520. https://doi.org/10.1634/theoncologist.2015-0267
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.